STING agonists enhance efficacy of bispecific T-cell engager AMG 330 in AML. (A, left) AMG 330 crosslinks CD3 as part of the T-cell receptor (TCR) on T cells with CD33 on AML cells and thereby triggers killing of AML cells. (A, right) The efficacy of AMG 330 is strongly increased by STING agonists cGAMP and diABZI, which stimulate a type I interferon response in AML cells. (B, left) Delta One T (DOT) cells may be superior effector cells. DOT cells efficiently kill AML cells through interaction of DNAM-1 receptor on DOT cells with polio virus receptor (PVR) on AML cells. Because DOT cells express the CD3/TCR complex, AMG 330 should also activate DOT cells, possibly synergistic with the DNAM1/PVR pathway. (B, right) The additional application of STING agonists is expected to further increase the susceptibility of AML cells through stimulation of the type I interferon response. Figure created with BioRender.com.